ImmunityBio’s 700% Revenue Boom Becomes Citadel’s Latest I‑Told‑You‑So
Benzinga • • business
Key Points:
- ImmunityBio Inc (NASDAQ: IBRX) reported a dramatic revenue increase for 2025, with approximately $113 million, representing a 700% year-over-year growth driven by its lead oncology therapy, Anktiva.
- Fourth quarter revenue surged 431% year-over-year to $38.3 million, highlighting rapid commercial scaling that outpaces typical oncology drug launches and shifts investor focus from trial risk to execution and demand.
- Hedge funds like Renaissance Technologies and Citadel Advisors anticipated this growth, increasing or initiating stakes based on expectations of faster-than-consensus revenue scaling rather than momentum chasing.
- Despite being viewed as a speculative biotech at around $5 per share, ImmunityBio's exceptional revenue growth is prompting investors to reconsider its
